Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients

Diabetes Care

Volumn 33, Issue 6, 2010, Pages 1320-1324

  Nielsen, Stine Elkjaer ^a   Sugaya, Takeshi ^b   Hovind, Peter ^a,c   Baba, Tsuneharu ^d   Parving, Hans Henrik ^e,f   Rossing, Peter ^a  

^a STENO DIABETES CENTER   (Denmark)

^b RIKEN KOBE INSTITUTE   (Japan)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d Hiroshima Prefectural Univ   (Japan)

^e Rigshospitalet   (Denmark)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; FATTY ACID BINDING PROTEIN; HEMOGLOBIN A1C; LIVER TYPE FATTY ACID BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAZARD RATIO; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; URINALYSIS; URINARY EXCRETION; ALBUMINURIA; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; URINE;

ADULT; ALBUMINURIA; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 77955063453     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2242     Document Type: Article

References (17)

1. Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In Brenner & Rector's The Kidney. 8th ed. Brenner BM, Ed. Boston, WB Saunders, 2008, p. 1265-1298
2. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the , EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008;31:1360-1366
3. Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In The Kidney. 6th ed. Brenner BM, Ed. Philadelphia, WB Saunders, 2000, p. 1731-1773
4. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992;288(Pt. 1):285-290
5. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004;165:1243-1255
6. Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, Baba T, Parving HH, Rossing P. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009;32:1684-1688
7. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004;328:1105
8. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258-1264
9. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005;28:2728-2732 (Pubitemid 43951167)
10. Kamijo A, Sugaya T, Tanaka Y, Yasuda T, Kimura K. Urinary excretion of liver-type fatty acid binding protein (L-FABP) as a useful predictor of future renal in dysfunction in type 2 diabetic nephropathy. Abstract. presented at Renal Week 27 Oct-1 Nov 2009, San Diego, CA
11. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005;145:125-133
12. Sejdiu I, Torffvit O. Decreased urinary concentration of Tamm-Horsfall protein is associated with development of renal failure and cardiovascular death within 20 years in type 1 but not in type 2 diabetic patients. Scand J Urol Nephrol 2008;42:168-174 (Pubitemid 351451008)
13. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992;288(Pt. 1):285-290
14. Sejdiu I, Torffvit O. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004;165:1243-1255
15. Yokoyama T, Kamijo-Ikemori A, Sugaya T, Hoshino S, Yasuda T, Kimura K. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 2009;174:2096-2106
16. Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins: their function and physiological significance. Prog Lipid Res 1996;35:243-282
17. Zimmerman AW, Veerkamp JH. Fatty-acid-binding proteins do not protect against induced cytotoxicity in a kidney cell model. Biochem J 2001;360:159-165